
Human Cyclin-A1 385-395, SLIAAAAFCLA
Description
About Human Cyclin-A1 385-395, SLIAAAAFCLA
The Human Cyclin-A1 Peptide (IEDB: 1075677) is a high quality epitope peptide for stimulation of antigen-specific T cells in T cell assays such as ELISPOT, ICS, cytotoxicity or proliferation assays. The Cyclin-A1 Peptide, H-SLIAAAAFCLA-OH (Uniprot: P78396 aa: 385-395) from JPT is produced under strict quality control and quality management.
Human Cyclin-A1 385-395, SLIAAAAFCLA - Specifications
- Peptide sequence: H-SLIAAAAFCLA-OH
- Amount: 1 mg
- Purity: Trial Grade: each peptide purified to > 90% (HPLC/MS)
- Counterion: TFA
- Delivery Format: Freeze-dried in glass vial
- Application(s): T-cell Immunity
- Condition(s)/Topic(s): Melanoma, Leukemia
- Standard Delivery Time: approx. 3 weeks
JPT’s Antigen Peptides
Find your antigen peptide and select the connected PepMix™ Peptide Pool for efficient immune monitoring, mapping of T cell epitopes or development of immunotherapy and vaccines. JPT Peptide Technologies has substantial, long-standing expertise in providing peptides, peptidomimetics, and proteins to the global scientific community. Our highly skilled and committed scientific staff ensures that the most appropriate methods and techniques are selected for every synthesis project. All our catalog peptides are provided with HPLC-MS analyses to confirm the identity and demonstrate the high quality of our peptides.
Not found what you are looking for? Take a look at our Peptide Synthesis Services!
Benefits of JPT’s Antigen Peptides
- All peptides are made in Germany
- Bulk orders or custom peptide snythesis upon request
- Synthesis protocols designed to avoid toxic contaminants and side products
- Provision of freeze dried aliquots for enhanced stability
- Proven track record for applications in clinical studies
- Order the connected PepMix™ Peptide Pool with your peptide!
References
References for Human Cyclin-A1 385-395, SLIAAAAFCLA
References:
Read References with JPT’s Antigen Peptides
Human Cyclin-A1 385-395, SLIAAAAFCLA has been described in:
Landscape mapping of shared antigenic epitopes and their cognate TCRs of tumor-infiltrating T lymphocytes in melanoma., Elife, 2020 (PMID: 32314731)
Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike., Cell Host Microbe, 2020 (PMID: 32157447)
Documentation
Documentation for Human Cyclin-A1 385-395, SLIAAAAFCLA
Properties
Properties of Human Cyclin-A1 385-395, SLIAAAAFCLA
Properties | Values |
---|---|
Application: | T-cell immunity |
Category: | Antigen Peptides |
Condition / Topic: | Leukemia, Melanoma |
Layout: | Freeze-dried in glass vial |
Organism: | Human |
Purity: | Trial Grade: each peptide purified to > 90% (HPLC/MS) |
Quantification: | No, Yes |
Further Information to Human Cyclin-A1 385-395, SLIAAAAFCLA
Information | Values |
---|---|
Sequence: | H-SLIAAAAFCLA-OH |
Specifications: | 11mer peptide as TFA salt |